ContextVision (CONTX) 주식 개요
소프트웨어 회사인 ContextVision AB(publ)는 아시아, 유럽 및 미국의 의료 시스템을 위한 이미지 분석 및 이미징을 제공하는 회사입니다. 자세히 보기
CONTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ContextVision AB (publ) 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | NOK 3.55 |
| 52주 최고가 | NOK 4.99 |
| 52주 최저가 | NOK 2.70 |
| 베타 | 0.22 |
| 1개월 변동 | 1.72% |
| 3개월 변동 | 4.41% |
| 1년 변동 | -27.70% |
| 3년 변동 | -59.29% |
| 5년 변동 | -80.95% |
| IPO 이후 변동 | -4.05% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.내러티브 업데이트 • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.내러티브 업데이트 • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.내러티브 업데이트 • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Recent updates
내러티브 업데이트 • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.내러티브 업데이트 • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.내러티브 업데이트 • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.내러티브 업데이트 • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.내러티브 업데이트 • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.내러티브 업데이트 • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).내러티브 업데이트 • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).내러티브 업데이트 • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.내러티브 업데이트 • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.내러티브 업데이트 • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.내러티브 업데이트 • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.분석 기사 • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...내러티브 업데이트 • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.분석 기사 • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...분석 기사 • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...분석 기사 • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...내러티브 업데이트 • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).분석 기사 • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...분석 기사 • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
새로운 내러티브 • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.분석 기사 • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...분석 기사 • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...분석 기사 • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...분석 기사 • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...분석 기사 • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...분석 기사 • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...분석 기사 • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...분석 기사 • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...주주 수익률
| CONTX | NO Healthcare Services | NO 시장 | |
|---|---|---|---|
| 7D | -3.5% | 3.6% | 3.2% |
| 1Y | -27.7% | -10.2% | 24.9% |
수익률 대 산업: CONTX은 지난 1년 동안 -10.2%의 수익을 기록한 Norwegian Healthcare Services 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: CONTX은 지난 1년 동안 24.9%를 기록한 Norwegian 시장보다 저조한 성과를 냈습니다.
주가 변동성
| CONTX volatility | |
|---|---|
| CONTX Average Weekly Movement | 7.6% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in NO Market | 12.4% |
| 10% least volatile stocks in NO Market | 3.3% |
안정적인 주가: CONTX는 지난 3개월 동안 Norwegian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: CONTX의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1989 | 43 | Gerald Potzsch | www.contextvision.se |
소프트웨어 회사인 ContextVision AB(publ)는 아시아, 유럽 및 미국의 의료 시스템에 이미지 분석 및 이미징을 제공하는 회사입니다. 초음파 이미지 품질 솔루션과 2D 이미지 향상 솔루션인 Rivent, 프리미엄 2D 이미지 향상 제품인 Rivent Plus, 3D 초음파 이미지 품질 향상 솔루션인 Rivent 3D, 영상의학, 심장학, 여성 건강, 수의학, 현장 진료 애플리케이션 등 다양한 분야의 진단용 휴대용 기기용 2D 이미지 향상 솔루션인 Rivent Mobile로 구성된 Rivent 플랫폼을 제공합니다. 또한 산란 보정 기능을 갖추고 방사선량을 줄이면서 이미지 품질을 향상시켜 방사선 촬영을 개선하는 알투미라 플랫폼(정적 애플리케이션용 알투미라, 동적 애플리케이션용 알투미라 플러스 등)을 제공합니다.
ContextVision AB (publ) 기초 지표 요약
| CONTX 기초 통계 | |
|---|---|
| 시가총액 | NOK 264.69m |
| 순이익 (TTM) | NOK 4.67m |
| 매출 (TTM) | NOK 112.45m |
56.6x
주가수익비율(P/E)2.4x
주가매출비율(P/S)CONTX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| CONTX 손익계산서 (TTM) | |
|---|---|
| 매출 | SEK 113.49m |
| 매출원가 | SEK 64.90m |
| 총이익 | SEK 48.59m |
| 기타 비용 | SEK 43.88m |
| 순이익 | SEK 4.72m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 27, 2026
| 주당순이익(EPS) | 0.063 |
| 총이익률 | 42.82% |
| 순이익률 | 4.16% |
| 부채/자본 비율 | 0% |
CONTX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 06:47 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ContextVision AB (publ)는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |